Hypervirulent and carbapenem-resistant Klebsiella pneumoniae: A global public health threat

T Lei, B Liao, LR Yang, Y Wang, X Chen - Microbiological Research, 2024 - Elsevier
The evolution of hypervirulent and carbapenem-resistant Klebsiella pneumoniae can be
categorized into three main patterns: the evolution of KL1/KL2-hvKp strains into CR-hvKp …

Antibiotic resistance: A global problem and the need to do more

FC Lessa, DM Sievert - Clinical Infectious Diseases, 2023 - academic.oup.com
The discovery of penicillin in 1928 and its initial use in the 1940s to treat serious infections
marked a turning point in modern medicine saving millions of lives [1]. However, antibiotic …

An increased prevalence of carbapenem-resistant hypervirulent Klebsiella pneumoniae associated with the COVID-19 pandemic

C Liu, J Guo, S Fan, W Guo, H Qi, S Baker, P Du… - Drug Resistance …, 2024 - Elsevier
Abstract Background Klebsiella pneumoniae (Kp) is a common community-acquired and
nosocomial pathogen. Carbapenem-resistant and hypervirulent (CR-hvKp) variants can …

Costs-effectiveness and cost components of pharmaceutical and non-pharmaceutical interventions affecting antibiotic resistance outcomes in hospital patients: a …

K Allel, MJ Hernández-Leal, NR Naylor… - BMJ Global …, 2024 - gh.bmj.com
Introduction Limited information on costs and the cost-effectiveness of hospital interventions
to reduce antibiotic resistance (ABR) hinder efficient resource allocation. Methods We …

Lives lost and disease burden related to antimicrobial resistance in the Americas can no longer be ignored

EA Undurraga, A Peters, CA Arias… - The Lancet Regional …, 2023 - thelancet.com
The emergence and spread of antimicrobial resistance (AMR) poses a substantial risk to
modern medicine and is widely recognised as one of the most daunting challenges of our …

[HTML][HTML] Impact of the COVID-19 pandemic on inpatient antibiotic and antifungal drug prescribing volumes in Germany

WV Kern, M Steib-Bauert, J Baumann, E Kramme… - Antibiotics, 2024 - mdpi.com
Background: Previous studies found that the coronavirus disease 2019 (COVID-19)
pandemic had a variable impact on the consumption of antimicrobial drugs in human …

Prevalence of carbapenem-resistant Enterobacterales with blaIMP-6 predominance in hospitals from 2018 to 2021 in Nara, Japan

R Kishi, R Nakano, A Nakano… - JAC-Antimicrobial …, 2024 - academic.oup.com
Objectives Despite the global health risk of carbapenem-resistant Enterobacterales (CRE),
especially carbapenemase-producing Enterobacterales (CPE), Japan reports a significantly …

Multispecies emergence of dual blaKPC/NDM carbapenemase-producing Enterobacterales recovered from invasive infections in Chile

AM Quesille-Villalobos, C Solar… - Antimicrobial Agents …, 2025 - journals.asm.org
Carbapenemase-producing carbapenem-resistant Enterobacterales (CP-CRE) represent a
significant global threat. The emergence of dual CP-CRE is particularly alarming, as they …

[HTML][HTML] Excess burden of antibiotic-resistant bloodstream infections: evidence from a multicentre retrospective cohort study in Chile, 2018–2022

K Allel, A Peters, H Haghparast-Bidgoli… - The Lancet Regional …, 2024 - thelancet.com
Background Antibiotic-resistant bloodstream infections (ARB BSI) cause an enormous
disease and economic burden. We assessed the impact of ARB BSI caused by high-and …

Ceftazidime/avibactam resistance is associated with PER-3-producing ST309 lineage in Chilean clinical isolates of non-carbapenemase producing Pseudomonas …

KD Soto, M Alcalde-Rico, JA Ugalde… - Frontiers in Cellular …, 2024 - frontiersin.org
Introduction Ceftazidime/avibactam (CZA) is indicated against multidrug-resistant
Pseudomonas aeruginosa, particularly those that are carbapenem resistant. CZA resistance …